DRIO vs. LUCD, OBIO, AVR, INFU, KRMD, SKIN, MGRM, ICAD, NSPR, and MBOT
Should you be buying DarioHealth stock or one of its competitors? The main competitors of DarioHealth include Lucid Diagnostics (LUCD), Orchestra BioMed (OBIO), Anteris Technologies Global (AVR), InfuSystem (INFU), KORU Medical Systems (KRMD), Beauty Health (SKIN), Monogram Orthopaedics (MGRM), iCAD (ICAD), InspireMD (NSPR), and Microbot Medical (MBOT). These companies are all part of the "medical equipment" industry.
DarioHealth vs.
DarioHealth (NASDAQ:DRIO) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.
In the previous week, Lucid Diagnostics had 1 more articles in the media than DarioHealth. MarketBeat recorded 3 mentions for Lucid Diagnostics and 2 mentions for DarioHealth. DarioHealth's average media sentiment score of 1.89 beat Lucid Diagnostics' score of 0.46 indicating that DarioHealth is being referred to more favorably in the media.
DarioHealth presently has a consensus target price of $1.50, indicating a potential upside of 107.58%. Lucid Diagnostics has a consensus target price of $3.50, indicating a potential upside of 171.32%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than DarioHealth.
DarioHealth has a net margin of -205.62% compared to Lucid Diagnostics' net margin of -1,069.87%. Lucid Diagnostics' return on equity of 0.00% beat DarioHealth's return on equity.
33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 10.9% of DarioHealth shares are owned by insiders. Comparatively, 8.8% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
DarioHealth received 199 more outperform votes than Lucid Diagnostics when rated by MarketBeat users. However, 68.97% of users gave Lucid Diagnostics an outperform vote while only 66.95% of users gave DarioHealth an outperform vote.
Lucid Diagnostics has lower revenue, but higher earnings than DarioHealth. Lucid Diagnostics is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.
DarioHealth has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.
Summary
Lucid Diagnostics beats DarioHealth on 10 of the 19 factors compared between the two stocks.
Get DarioHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DarioHealth Competitors List
Related Companies and Tools
This page (NASDAQ:DRIO) was last updated on 5/1/2025 by MarketBeat.com Staff
